Gregory Hayes

Gregory Hayes has over 20 years of experience in the biopharmaceutical industry. Gregory began their career in 1997 as a Graduate Student at the Terry Fox Laboratory (BC Cancer Agency) & Jonsson Comprehensive Cancer Center (UCLA). In 2001, they became a Post-Doctoral Fellow (Bone Marrow Transplantation) at Rush Cancer Institute. Gregory then moved to Mayo Clinic Cancer Center in 2002 as a Post-Doctoral Fellow. In 2006, they joined KineMed Inc. as a Scientist, Oncology. In 2008, they became a Scientist - Sr Scientist at MedImmune. In 2012, they joined Igenica Inc. as a Sr Scientist - Pre-Clinical Development. In 2014, they moved to BioMarin Pharmaceutical Inc. as a Director, Translational Sciences (Clinical Diagnostics) and an Assoc. Director, Translational Sciences. In 2020, they joined BridgeBio as a Senior Director, Head of Biomarker Development. Most recently, in 2022, they were appointed as the Vice President, Translational Medicine at Kurome Therapeutics, Inc.

Gregory Hayes obtained a Doctor of Philosophy (Ph.D.) in Medicine (Pathology) from The University of British Columbia between 1997 and 2002. Prior to that, they completed a Bachelor of Science (BSc) in Genetics from the University of Alberta between 1991 and 1996.